The American Journal of Medicine
Volume 121, Issue 9 , Pages 744-747 , September 2008

Treatment of Osteoporosis: All the Questions We Still Cannot Answer

  • Michel Laroche

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to Michel Laroche, Service de Rhumatologie, CHU Rangueil-Larrey, Hôpital Rangueil-Larrey, 24 chemin de Pouvourville, 31059 Toulouse Cedex 9, France

References 

  1. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet. 2002;359:2018–2026
  2. Clifford JR, Brown SA. A rational approach to evidence gaps in the management of osteoporosis. Am J Med. 2005;118:1183–1189
  3. Fleisch H, Russell RG, Francis MD. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science. 1969;165:1262–1264
  4. Fleisch H, Felix R. Diphosphonates. Calcif Tissue Int. 1979;27:91–94
  5. Roux C, Cormier C, Fardellone P. Réduction précoce du risque fracturaire sous risedronate. Rev Rhum. 2002;1039:10–11
  6. Li Z, Meredith MP, Hoseyni MS. A method to assess the proportion of treatment effect explained by a surrogate endpoint. Stat Med. 2001;20:3175–3188
  7. Cummings SR, Karpf DB, Harris F, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med. 2002;112:281–289
  8. Davison KS, Siminoski K, Adachi JD, et al. The effects of antifracture therapies on the components of bone strength: assessment of fracture risk today and in the future. Semin Arthritis Rheum. 2006;36:10–21
  9. Boivin GY, Chavassieux PM, Santora AC, et al. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone. 2000;27:687–694
  10. Paschalis E, Phipps RJ. Long-term treatment with risedronate preserves bone quality. J Bone Miner Res. 2003;18(suppl 2):S259
  11. Borah B, Dufresne TE, Chmielewski PA, et al. Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone. 2004;34:736–746
  12. Camacho NP, Carroll P, Raggio CL. Fourier transform infrared imaging spectroscopy (FT-IRIS) of mineralization in bisphosponate-treated oim/oim mice. Calcif Tissue Int. 2003;72:604–609
  13. Ettinger B, Black DM, Mitlak BH, et al. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA. 1999;282:637–645
  14. Harris ST, Watts NB, Genant NK, et al. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group Effects of risedronate treatment on vertebral and non-vertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA. 1999;282:1344–1352
  15. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone 1-34 on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434–1441
  16. Black DM, Thompson DE, Bauer DC, et al. FIT Research Group Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. J Clin Endocrinol Metab. 2000;85:4118–4124
  17. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med. 2004;350:459–468
  18. Chesnut CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19:1241–1249
  19. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment for postmenopausal osteoporosis. N Engl J Med. 2007;356:1809–1822
  20. Johnell O, Scheele WH, Lu Y, et al. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2002;87:985–992
  21. Deal C, Omizo M, Schwartz EN, et al. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: result from a 6-months double-blind placebo-controlled trial. J Bone Miner Res. 2005;11:1905–1911
  22. Neele SJ, Evertz R, De Valk-Der Roo G, et al. Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women. Bone. 2002;45:99–603
  23. Ettinger B, San Martin J, Crans G, Pavo I. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res. 2004;19:745–751
  24. Blake GM, Fogelman I. Theoretical model for the interpretation of BMD scans in patients stopping strontium ranelate treatment. J Bone Miner Res. 2006;21:1417–1424
  25. Ensrud KE, Barrett-Connor EL, Schwartz A, et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res. 2004;19:1259–1269
  26. Mellstrom DD, Sorensen OH, Goemaere S, et al. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int. 2004;75:462–468
  27. Martino S, Disch D, Dowsett SA, et al. Safety assessment of raloxifene over eight years in a clinical trial setting. Curr Med Res Opin. 2005;21:1441–1452
  28. Bone HG, Hosking D, Devogelaer JP, et al. Alendronate Phase III Osteoporosis Treatment Study Group (Ten years' experience with alendronate for osteoporosis in postmenopausal women). N Engl J Med. 2004;350:1189–1199

PII: S0002-9343(08)00473-7

doi: 10.1016/j.amjmed.2008.03.048

The American Journal of Medicine
Volume 121, Issue 9 , Pages 744-747 , September 2008

Article Tools